GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apollo Endosurgery Inc (NAS:APEN) » Definitions » PE Ratio

Apollo Endosurgery (Apollo Endosurgery) PE Ratio : At Loss (As of May. 18, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Apollo Endosurgery PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-18), Apollo Endosurgery's share price is $10.00. Apollo Endosurgery's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.98. Therefore, Apollo Endosurgery's PE Ratio for today is At Loss.

During the past 13 years, Apollo Endosurgery's highest PE Ratio was 6.25. The lowest was 0.00. And the median was 5.04.

Apollo Endosurgery's EPS (Diluted) for the three months ended in Dec. 2022 was $-0.23. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.98.

As of today (2024-05-18), Apollo Endosurgery's share price is $10.00. Apollo Endosurgery's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.98. Therefore, Apollo Endosurgery's PE Ratio without NRI ratio for today is At Loss.

During the past 13 years, Apollo Endosurgery's highest PE Ratio without NRI was 6.25. The lowest was 0.00. And the median was 5.04.

Apollo Endosurgery's EPS without NRI for the three months ended in Dec. 2022 was $-0.23. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.98.

During the past 3 years, the average EPS without NRI Growth Rate was 8.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 38.60% per year.

During the past 13 years, Apollo Endosurgery's highest 3-Year average EPS without NRI Growth Rate was 77.10% per year. The lowest was -41.90% per year. And the median was 29.20% per year.

Apollo Endosurgery's EPS (Basic) for the three months ended in Dec. 2022 was $-0.23. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.98.

Back to Basics: PE Ratio


Apollo Endosurgery PE Ratio Historical Data

The historical data trend for Apollo Endosurgery's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollo Endosurgery PE Ratio Chart

Apollo Endosurgery Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Apollo Endosurgery Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Apollo Endosurgery's PE Ratio

For the Medical Devices subindustry, Apollo Endosurgery's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollo Endosurgery's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Apollo Endosurgery's PE Ratio distribution charts can be found below:

* The bar in red indicates where Apollo Endosurgery's PE Ratio falls into.



Apollo Endosurgery PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Apollo Endosurgery's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=10.00/-0.980
=-10.2(At Loss)

Apollo Endosurgery's Share Price of today is $10.00.
Apollo Endosurgery's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.98.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Apollo Endosurgery  (NAS:APEN) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Apollo Endosurgery PE Ratio Related Terms

Thank you for viewing the detailed overview of Apollo Endosurgery's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollo Endosurgery (Apollo Endosurgery) Business Description

Traded in Other Exchanges
N/A
Address
1120 S. Capital of Texas Highway, Building 1, Suite 300, Austin, TX, USA, 78746
Apollo Endosurgery Inc is active in the healthcare sector based in the United States. As a developer of medical devices, Apollo focuses on addressing obesity, as well as other gastrointestinal disorders. Its products are used by general surgeons, bariatric surgeons and gastroenterologists in a variety of settings to provide interventional therapy to patients who suffer from obesity. The company's products include the OverStitch Endoscopic Suturing System, X-Tack Endoscopic HeliX Tacking System, and the Orbera Intragastric Balloon System.
Executives
Antal Rohit Desai 10 percent owner C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Sharon O'keefe director C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Jeannette Bankes director ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffrey G. Black officer: Chief Financial Officer 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Mike Gutteridge officer: VP, Int'l Sales and Marketing 1120 S. CAPITAL OF TEXAS HIGHWAY, BUILDING 1, SUITE #300, AUSTIN TX 78746
Cpmg Inc 10 percent owner 4215 WEST LOVERS LANE, SUITE 100, DALLAS TX 75209
Mcgaughy R Kent Jr director, 10 percent owner 500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Chas Mckhann director, officer: President and CEO 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Pacitti director C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
John R Barr director VI TECHNOLOGIES INC, 134 COOLIDGE AVENUE, WATERTOWN MA 02472
Neil Gagnon 10 percent owner 1370 AVENUE OF THE AMERICAS, 24TH FLOOR, NEW YORK NY 10019
Traweek James W Jr 10 percent owner 2000 MCKINNEY AVE, SUITE 2125, DALLAS TX 75201
Todd Newton director, officer: Chief Executive Officer 1120 S CAPITAL OF TX HWY, BUILDING ONE, STE 300, AUSTIN TX 78746
Stonepine Capital, L.p. 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Matthew S Crawford director, 10 percent owner 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746

Apollo Endosurgery (Apollo Endosurgery) Headlines